不可切除局部晚期食管鳞癌维持治疗的研究进展  

Research progress in maintenance therapy for unresectable locally advanced esophageal squamous cell carcinoma

作　　者：游传宇(综述) 皈燕(审校)[1] Chuanyu You;Yan Gui(Department of Oncology,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China)

机构地区：[1]川北医学院附属医院肿瘤科,四川省南充市637000

出　　处：《中国肿瘤临床》2025年第5期253-258,共6页Chinese Journal of Clinical Oncology

摘　　要：食管癌是中国恶性肿瘤相关死亡的主要原因之一,其中以食管鳞癌(esophageal squamous cell carcinoma,ESCC)最常见,大部分患者就诊时已处于中晚期,不宜手术治疗。不可切除局部晚期食管鳞癌患者目前临床中治疗手段有限,且采用根治性同步放化疗(definitive concurrent chemoradiotherapy,dCCRT)等一线治疗后,仍面临着高复发、高转移的风险。近年来靶向药物、免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)等研究为临床治疗提供了更多选择,但对于是否需要通过维持治疗使患者生存获益,以及采取何种维持治疗方式等,临床中尚无明确定论。本文对不可切除局部晚期食管鳞癌患者后续维持治疗的研究进展进行综述,旨在为进一步优化综合治疗策略和制定个性化治疗方案提供参考。Esophageal cancer is one of the leading causes of cancer-related mortality in China,and esophageal squamous cell carcinoma(ES-CC)is the predominant histological subtype.Most people are diagnosed with ESCC at an advanced stage and are thus ineligible for surgical resection.The current therapeutic options for unresectable locally advanced ESCC are limited.The risks of recurrence and metastasis are high after first-line treatment,such as with definitive concurrent chemoradiotherapy(dCCRT).Recent advances in targeted therapies and im-mune checkpoint inhibitors(ICIs)have expanded the clinical treatment options for ESCC.However,no consensus has been reached on whether maintenance therapy provides survival benefits or which maintenance strategies should be prioritized.We provide a systematic re-view of the progress of research on postprimary maintenance therapy for patients with unresectable locally advanced ESCC,with the goal of optimizing comprehensive treatment strategies and providing information for personalized therapeutic decision making.

关 键 词：食管鳞癌 维持治疗 维持化疗 免疫检查点抑制剂 分子靶向治疗 

分 类 号：R735.1[医药卫生—肿瘤]